Article Details

Sarepta Therapeutics (SRPT) Receives a Hold from Morgan Stanley

Retrieved on: 2021-04-19 18:44:12

Tags for this article:

Click the tags to see associated articles and topics

Sarepta Therapeutics (SRPT) Receives a Hold from Morgan Stanley. View article details on hiswai:

Excerpt

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Sarepta Therapeutics (SRPT) today and set a price target of $93.00.

Article found on: www.smarteranalyst.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo